VIDEO: IRIS Registry data show safety, efficacy of Dextenza
BOSTON — In this Healio Video Perspective from the ASCRS meeting, Steven M. Silverstein, MD, FACS, ABO, discusses IRIS Registry data related to Dextenza.
The data from 53,000 eyes that received Dextenza (dexamethasone ophthalmic insert 0.4 mg, Ocular Therapeutix) after cataract surgery and more than 1 million patients who received eye drops are “astoundingly similar in that they both have very low incidence of adverse events measured by inflammation, [cystoid macular edema], endophthalmitis, dacryocystitis and corneal edema,” Silverstein said.
“Both from the standpoint of safety and efficacy, the IRIS Registry gives us the intelligence to recognize that the intracanalicular insert is remarkably powerful,” he said.
Collapse
Silverstein SM, et al. Incidence of safety events following cataract surgery with intracanalicular dexamethasone: A study of 50,000 eyes using the IRIS Registry. Presented at: American Society of Cataract and Refractive Surgery meeting; April 5-8, 2024; Boston.
Read more about